Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

GC Biopharma Corp. (006280) Stock Price & Analysis

006280 Stock Chart & Stats

$130,200.00-$1,800.00(-1.36%)
At close: 3:30 PM GMT+9
$115,000$120,000$125,000$130,0003 Aug18 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$128,100.00 - $133,400.00
52-Week Range
$105,900.00 - $183,800.00
Previous Close
$132,000.00
Volume
N/A
Average Volume (3M)
17.27K
Market Cap
KRW 1.49T
Enterprise Value
KRW 2.36T
Total Cash (Recent Filing)
KRW 44.66B
Total Debt (Recent Filing)
KRW 938.85B
Price to Earnings (P/E)
―
Beta
0.20
Next Earnings
Nov 03, 2026 (Est.)
EPS Estimate
N/A
Last Dividend Ex-Date
Mar 30, 2026
Dividend Yield
1.15%

Bulls Say, Bears Say

Bulls Say

Plasma-derived Therapy Platform

The company operates in plasma-derived therapies with an established portfolio spanning immunoglobulin, albumin-based products, and other medicines. This specialized platform can support recurring clinical demand and provides a foundation for serving both domestic providers and international markets over time.

Improved Cash Generation

The shift to positive trailing-twelve-month operating and free cash flow is a constructive improvement in internal funding capacity. Although the pattern has been volatile, stronger cash conversion can support ongoing operations and reduce dependence on external financing if maintained.

Substantial Equity Cushion

A sizable equity base relative to total assets provides the company with a financial cushion while it works through weaker profitability and higher leverage. This balance-sheet support can improve resilience and preserve flexibility for operations during the next several quarters.

Bears Say

Recurring Losses And Margin Pressure

The move from prior profitability to recurring net losses indicates that the business is not consistently converting revenue into earnings. Compressed margins reduce the capacity to fund growth internally and make sustained recovery dependent on improving operating economics.

Declining TTM Revenue

The trailing-twelve-month revenue decline signals weaker recent demand after relatively stable and modestly growing annual periods. If this softness persists, it can limit operating leverage, make margin recovery harder, and constrain the company’s ability to rebuild earnings.

Rising Leverage And Negative Returns

Higher debt-to-equity increases reliance on debt funding at the same time that invested capital is producing negative returns. This combination can reduce financial flexibility, increase pressure on future cash generation, and constrain capital allocation until profitability improves.

GC Biopharma Corp. News

006280 FAQ

What was GC Biopharma Corp.’s price range in the past 12 months?
GC Biopharma Corp. lowest stock price was $105900.00 and its highest was $183800.00 in the past 12 months.
What is GC Biopharma Corp.’s market cap?
GC Biopharma Corp.’s market cap is ₩1.49T.
When is GC Biopharma Corp.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were GC Biopharma Corp.’s earnings last quarter?
GC Biopharma Corp. released its earnings results on Jul 31, 2026. The company reported $169.42 earnings per share for the quarter, missing the consensus estimate of $973.79 by -$804.37.
Is GC Biopharma Corp. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does GC Biopharma Corp. pay dividends?
GC Biopharma Corp. pays a ― dividend of $1,500 which represents an annual dividend yield of 1.15%. See more information on GC Biopharma Corp. dividends here
What is GC Biopharma Corp.’s EPS estimate?
GC Biopharma Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GC Biopharma Corp. have?
GC Biopharma Corp. has 11,686,538 shares outstanding.
What happened to GC Biopharma Corp.’s price movement after its last earnings report?
GC Biopharma Corp. reported an EPS of $169.42 in its last earnings report, missing expectations of $973.79. Following the earnings report the stock price went up 1.489%.
Which hedge fund is a major shareholder of GC Biopharma Corp.?
Currently, no hedge funds are holding shares in KR:006280
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology